

Rene Rodriguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2762954/publications.pdf>

Version: 2024-02-01

54
papers

2,550
citations

186209

28
h-index

189801

50
g-index

54
all docs

54
docs citations

54
times ranked

4009
citing authors

#	ARTICLE	IF	CITATIONS
1	Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. <i>Stem Cells International</i> , 2016, 2016, 1-13.	1.2	164
2	Chk1 and p21 Cooperate to Prevent Apoptosis during DNA Replication Fork Stress. <i>Molecular Biology of the Cell</i> , 2006, 17, 402-412.	0.9	163
3	Sarcoma treatment in the era of molecular medicine. <i>EMBO Molecular Medicine</i> , 2020, 12, e11131.	3.3	154
4	Bone microenvironment signals in osteosarcoma development. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3097-3113.	2.4	147
5	Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2552-2565.	1.6	129
6	Modeling sarcomagenesis using multipotent mesenchymal stem cells. <i>Cell Research</i> , 2012, 22, 62-77.	5.7	125
7	Enrichment of Human ESC-Derived Multipotent Mesenchymal Stem Cells with Immunosuppressive and Anti-Inflammatory Properties Capable to Protect Against Experimental Inflammatory Bowel Disease. <i>Stem Cells</i> , 2011, 29, 251-262.	1.4	119
8	ATR and Chk1 Suppress a Caspase-3-Dependent Apoptotic Response Following DNA Replication Stress. <i>PLoS Genetics</i> , 2009, 5, e1000324.	1.5	109
9	Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. <i>Journal of Experimental Medicine</i> , 2009, 206, 3131-3141.	4.2	109
10	Deficiency in p53 but not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells <i>in vitro</i> and Initiates Leiomyosarcoma <i>in vivo</i> . <i>Cancer Research</i> , 2010, 70, 4185-4194.	0.4	96
11	Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem Cells. <i>Neoplasia</i> , 2009, 11, 397-IN9.	2.3	89
12	Bone Environment is Essential for Osteosarcoma Development from Transformed Mesenchymal Stem Cells. <i>Stem Cells</i> , 2014, 32, 1136-1148.	1.4	89
13	The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of <i>in vivo</i> sarcoma development. <i>Oncogene</i> , 2013, 32, 4970-4980.	2.6	79
14	Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangement. <i>Leukemia</i> , 2011, 25, 400-410.	3.3	65
15	Residual Expression of the Reprogramming Factors Prevents Differentiation of iPSC Generated from Human Fibroblasts and Cord Blood CD34+ Progenitors. <i>PLoS ONE</i> , 2012, 7, e35824.	1.1	61
16	Pyruvate Plays a Main Role in the Antitumoral Selectivity of Cold Atmospheric Plasma in Osteosarcoma. <i>Scientific Reports</i> , 2019, 9, 10681.	1.6	61
17	Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation. <i>Stem Cells</i> , 2013, 31, 2061-2072.	1.4	59
18	FUS-CHOP Fusion Protein Expression Coupled to p53 Deficiency Induces Liposarcoma in Mouse but Not in Human Adipose-Derived Mesenchymal Stem/Stromal Cells. <i>Stem Cells</i> , 2011, 29, 179-192.	1.4	57

#	ARTICLE	IF	CITATIONS
19	Inactivation of p53 in Human Keratinocytes Leads to Squamous Differentiation and Shedding via Replication Stress and Mitotic Slippage. <i>Cell Reports</i> , 2014, 9, 1349-1360.	2.9	48
20	Sarcoma Stem Cell Heterogeneity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1123, 95-118.	0.8	41
21	Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma. <i>Oncotarget</i> , 2016, 7, 30935-30950.	0.8	40
22	Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of <i>MRE11</i> . <i>Clinical Cancer Research</i> , 2008, 14, 5476-5483.	3.2	39
23	Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. <i>Scientific Reports</i> , 2016, 6, 27878.	1.6	38
24	Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. <i>Cell Death and Differentiation</i> , 2008, 15, 889-898.	5.0	37
25	FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway. <i>Neoplasia</i> , 2018, 20, 44-56.	2.3	35
26	Human Bone Marrow Stromal Cells Lose Immunosuppressive and Anti-inflammatory Properties upon Oncogenic Transformation. <i>Stem Cell Reports</i> , 2014, 3, 606-619.	2.3	33
27	Multipotent Mesenchymal Stromal Cells: Clinical Applications and Cancer Modeling. <i>Advances in Experimental Medicine and Biology</i> , 2012, 741, 187-205.	0.8	32
28	Polyinosinic acid induces TNF and NO production as well as NF- κ B and AP-1 transcriptional activation in the monocytemacrophage cell line RAW 264.7. <i>Inflammation Research</i> , 2005, 54, 328-337.	1.6	31
29	DNA replication stress in CHK1-depleted tumour cells triggers premature (S-phase) mitosis through inappropriate activation of Aurora kinase B. <i>Cell Death and Disease</i> , 2014, 5, e1253-e1253.	2.7	27
30	Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas. <i>Journal of Clinical Medicine</i> , 2021, 10, 2621.	1.0	23
31	Trabectedin and Camptothecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models. <i>Neoplasia</i> , 2017, 19, 460-470.	2.3	22
32	SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications. <i>Cancers</i> , 2020, 12, 964.	1.7	21
33	The Globoseries Glycosphingolipid SSEA-4 Is a Marker of Bone Marrow-Derived Clonal Multipotent Stromal Cells In Vitro and In Vivo. <i>Stem Cells and Development</i> , 2013, 22, 1387-1397.	1.1	20
34	New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth. <i>Journal of Clinical Medicine</i> , 2019, 8, 455.	1.0	18
35	Impaired Condensin Complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL. <i>Blood</i> , 2020, 136, 313-327.	0.6	16
36	Distinctive Expression and Amplification of Genes at 11q13 in Relation to HPV Status with Impact on Survival in Head and Neck Cancer Patients. <i>Journal of Clinical Medicine</i> , 2018, 7, 501.	1.0	15

#	ARTICLE	IF	CITATIONS
37	GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF- β 2. <i>Cell Death and Disease</i> , 2020, 11, 985.	2.7	14
38	The SRC Inhibitor Dasatinib Induces Stem Cell-Like Properties in Head and Neck Cancer Cells that are Effectively Counteracted by the Mithralog EC-8042. <i>Journal of Clinical Medicine</i> , 2019, 8, 1157.	1.0	12
39	The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas. <i>International Journal of Cancer</i> , 2019, 145, 254-266.	2.3	12
40	Effect of Vinca alkaloids on ER β levels and Estradiol-induced responses in MCF-7 cells. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 81-89.	1.1	11
41	Isolation and characterization of nuda9 from mouse macrophages, a gene implicated in the inflammatory response through the regulation of PAF-AH(I) activity. <i>FEBS Letters</i> , 2007, 581, 3057-3062.	1.3	11
42	Role of Activator Protein-1 Complex on the Phenotype of Human Osteosarcomas Generated from Mesenchymal Stem Cells. <i>Stem Cells</i> , 2018, 36, 1487-1500.	1.4	11
43	Mithramycin delivery systems to develop effective therapies in sarcomas. <i>Journal of Nanobiotechnology</i> , 2021, 19, 267.	4.2	11
44	The Differential Impact of SRC Expression on the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2019, 11, 1644.	1.7	9
45	The Mouse Tumor Necrosis Factor Receptor 2 Gene: Genomic Structure and Characterization of the Two Transcripts. <i>Genomics</i> , 1998, 52, 79-89.	1.3	8
46	The Novel Role of SOX2 as an Early Predictor of Cancer Risk in Patients with Laryngeal Precancerous Lesions. <i>Cancers</i> , 2019, 11, 286.	1.7	8
47	Nano-Encapsulation of Mithramycin in Transfersomes and Polymeric Micelles for the Treatment of Sarcomas. <i>Journal of Clinical Medicine</i> , 2021, 10, 1358.	1.0	8
48	Circulating cancer cells in division in an early breast cancer patient. <i>Annals of Oncology</i> , 2011, 22, 2150-2151.	0.6	7
49	TNF triggers mitogenic signals in NIH 3T3 cells but induces apoptosis when the cell cycle is blocked. <i>European Cytokine Network</i> , 2007, 18, 172-80.	1.1	5
50	Addressing Doxorubicin Resistance in Bone Sarcomas Using Novel Drug-Resistant Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6425.	1.8	5
51	Proof of concept for the use of trained sniffer dogs to detect osteosarcoma. <i>Scientific Reports</i> , 2022, 12, 6911.	1.6	4
52	SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
53	Candidate biomarkers of transformed mesenchymal stromal/stem cells by quantitative proteomics and glycoproteomics. <i>Experimental Hematology</i> , 2016, 44, S86-S87.	0.2	0
54	Cancer stem cells and clonal evolution in bone sarcomas. , 2022, , 371-391.		0